Clinical Trials Logo

Primary Hypertension clinical trials

View clinical trials related to Primary Hypertension.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06116357 Not yet recruiting - Clinical trials for Primary Hypertension

The Safety and Efficacy of Carotid Body Modulation Therapy in Hypertensive Patients by External Ultrasonic Micro-bubble

Start date: December 1, 2023
Phase: N/A
Study type: Interventional

The investigators intend to find a noninvasive method for CB modulation therapy and find a simple and convenient indicator for assessing CB activity. This study was designed to evaluate the safety and efficacy of carotid body modulation therapy in hypertensive patients by external ultrasonic micro-bubble and also identify the association between CB volume and CB activity.

NCT ID: NCT06091176 Not yet recruiting - Clinical trials for Essential Hypertension

Assessment of Efficacy and Safety of Amicomed®, for the Management of Essential Hypertension

Start date: November 1, 2024
Phase: N/A
Study type: Interventional

This is a multicenter, randomized, single-blind, parallel-group study to evaluate the efficacy and safety of Amicomed® compared with Usual Care (UC) over a 24-week treatment period in subjects with essential hypertension (mean, home based systolic blood pressure (SBP) ≥ 140 and/or diastolic blood pressure DBP ≥ 90 mm Hg on Day 1).

NCT ID: NCT05917275 Not yet recruiting - Clinical trials for Primary Hypertension

Multi-Omics to Predict the Blood Pressure Response to Antihypertensives

HT-PREDICT
Start date: October 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to develop biomarkers composed of multiple OMICs (MOMICs) for prediction of blood pressure response to antihypertensive drugs in the treatment of primary hypertension. The main objectives are: - Primary objective: - To identify MOMICs biomarkers that predict the response in 24-hour blood pressure to antihypertensive treatment for each treatment group (olmesartan, amlodipine, hydrochlorothiazide, olmesartan/amlodipine) - Secondary objectives: - To identify a MOMICs biomarker that predict the response in night-time blood pressure to anti-hypertensive treatment for each treatment group (olmesartan, amlodipine, hydrochlorothiazide, olmesartan/amlodipine) - To identify MOMICs biomarkers that predict side effects, including changes in QoLof olmesartan, amlodipine and hydrochlorothiazide. - Exploratory objective: - To assess changes in MOMICs biomarkers induced by each drug Participants will undergo three 4-week treatment periods: - Each subject receives 3 out of 4 possible treatments (olmesartan, amlodipine, hydrochlorothiazide, olmesartan/amlodipine). - Before and after each treatment period OMICS measurements and an ABPM are performed. - At the end of each treatment period blood is sampled for drug level testing to assess adherence. - Electrolytes and kidney function are checked 5-7 days after start of each treatment period.

NCT ID: NCT03491813 Not yet recruiting - Clinical trials for Primary Hypertension

Comparisonbetween Primary Hypertension Monitoring Methods for Detection of Early Kidney Dysfunction

Start date: August 1, 2019
Phase:
Study type: Observational

The present study aims to show the difference of blood pressure monitored centrally and automated BP monitoring among patients with primary hypertension for early detection of kidney dysfunction

NCT ID: NCT02901704 Not yet recruiting - Clinical trials for Primary Hypertension

Renal Denervation by Iberis MultiElectrode Renal Denervation System in Patients With Primary Hypertension

Iberis-HTN
Start date: December 2016
Phase: Phase 3
Study type: Interventional

The purpose of Iberis-HTN trial is to evaluate the safety and effectiveness of renal denervation in subjects with primary hypertension by using Iberis multielectrode renal denervation system